⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608960 | 1.00 | — | — | |
| SCHEMBL17784330 | 1.00 | — | — | |
| SCHEMBL9482878 | 0.96 | HIF1A (0.50) | — | |
| SCHEMBL24247 | 0.84 | — | — | |
| SCHEMBL2208868 | 0.84 | — | — | |
| SCHEMBL19874577 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL30449038 | 0.81 | — | — | |
| Lithium SCHEMBL29434589 | 0.81 | — | — | |
| SCHEMBL28736431 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL3253492 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151505-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS N.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | disclosed |
| CN-1360502-B | Dopamine D3Use of receptor ligands for the production of a medicament for the treatment of renal dysfunction | BASF AG | 2010-08-04 | — | — | CN | disclosed |
| CN-101524356-A | Use of dopamine D3 receptor ligands for production of drugs for treating renal function disorders | ABBOT SHARES INC (DE) | 2009-09-09 | — | — | CN | disclosed |
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | disclosed |
| EP-1176963-B1 | USE OF DOPAMINE D 3 RECEPTOR ANTAGONISTS FOR PRODUCING MEDICAMENTS FOR TREATING KIDNEY DISORDERS | ABBOTT GMBH & CO KG (DE) | 2004-12-15 | — | — | EP | disclosed |
| EP-0877744-B1 | SUBSTITUTED AZA- AND DIAZACYCLOHEPTANE AND CYCLOOCTANE COMPOUNDS AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-05-08 | — | — | US | disclosed |
| EP-1272187-A1 | USE OF DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-08 | — | — | EP | disclosed |
| CN-1360502-A | Dopamine D3Use of receptor ligands for the production of a medicament for the treatment of renal dysfunction | BASF AG (DE) | 2002-07-24 | — | — | CN | disclosed |
| US-6352981-B1 | TREAT DISORDERS WHICH RESPOND TO DOPAMINE D.SUB.3 LIGANDS SUCH AS SCHISTOSOMIASIS, SCHIZOPHRENIA, DEPRESSION, NEUROSES OR PSYCHOSES | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| WO-2001072306-A1 | USE OF DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-04 | — | — | WO | disclosed |
| US-6214822-B1 | PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| EP-0877744-A1 | SUBSTITUTED AZA- AND DIAZACYCLOHEPTANE AND CYCLOOCTANE COMPOUNDS AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997025324-A1 | SUBSTITUTED AZA- AND DIAZACYCLOHEPTANE AND CYCLOOCTANE COMPOUNDS AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-07-17 | — | — | WO | disclosed |